|
GSK PLC (GSK) تقييم DCF |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
GSK plc (GSK) Bundle
تقييم آفاق GSK PLC المالية مثل خبير! تأتي حاسبة DCF (GSK) هذه مع بيانات مالية مملوءة مسبقًا وتتيح لك المرونة الكاملة لتعديل نمو الإيرادات ، WACC ، الهوامش ، وغيرها من الافتراضات الحرجة التي تتماشى مع توقعاتك.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 44,663.8 | 44,683.4 | 38,409.3 | 39,724.4 | 41,097.1 | 40,365.8 | 39,647.5 | 38,942.0 | 38,249.1 | 37,568.4 |
| Revenue Growth, % | 0 | 0.04398956 | -14.04 | 3.42 | 3.46 | -1.78 | -1.78 | -1.78 | -1.78 | -1.78 |
| EBITDA | 13,310.5 | 10,159.0 | 11,302.5 | 11,969.2 | 8,733.9 | 10,765.2 | 10,573.7 | 10,385.5 | 10,200.7 | 10,019.2 |
| EBITDA, % | 29.8 | 22.74 | 29.43 | 30.13 | 21.25 | 26.67 | 26.67 | 26.67 | 26.67 | 26.67 |
| Depreciation | 3,079.4 | 2,779.5 | 2,812.2 | 3,004.7 | 3,341.4 | 2,916.9 | 2,865.0 | 2,814.0 | 2,764.0 | 2,714.8 |
| Depreciation, % | 6.89 | 6.22 | 7.32 | 7.56 | 8.13 | 7.23 | 7.23 | 7.23 | 7.23 | 7.23 |
| EBIT | 10,231.1 | 7,379.6 | 8,490.3 | 8,964.5 | 5,392.6 | 7,848.3 | 7,708.7 | 7,571.5 | 7,436.8 | 7,304.4 |
| EBIT, % | 22.91 | 16.52 | 22.1 | 22.57 | 13.12 | 19.44 | 19.44 | 19.44 | 19.44 | 19.44 |
| Total Cash | 8,343.6 | 5,678.1 | 10,317.5 | 6,538.7 | 4,864.7 | 6,987.1 | 6,862.8 | 6,740.7 | 6,620.7 | 6,502.9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 7,268.2 | 8,181.2 | 7,141.2 | 7,734.5 | .0 | 5,864.8 | 5,760.4 | 5,657.9 | 5,557.2 | 5,458.3 |
| Account Receivables, % | 16.27 | 18.31 | 18.59 | 19.47 | 0 | 14.53 | 14.53 | 14.53 | 14.53 | 14.53 |
| Inventories | 7,853.7 | 7,574.7 | 6,740.4 | 7,201.4 | 7,425.4 | 7,127.1 | 7,000.3 | 6,875.7 | 6,753.3 | 6,633.2 |
| Inventories, % | 17.58 | 16.95 | 17.55 | 18.13 | 18.07 | 17.66 | 17.66 | 17.66 | 17.66 | 17.66 |
| Accounts Payable | 5,706.9 | 5,940.1 | 5,063.8 | 4,868.6 | 4,534.6 | 5,049.3 | 4,959.5 | 4,871.2 | 4,784.6 | 4,699.4 |
| Accounts Payable, % | 12.78 | 13.29 | 13.18 | 12.26 | 11.03 | 12.51 | 12.51 | 12.51 | 12.51 | 12.51 |
| Capital Expenditure | -2,932.7 | -3,839.1 | -2,957.6 | -3,070.2 | -3,905.9 | -3,236.6 | -3,179.0 | -3,122.5 | -3,066.9 | -3,012.3 |
| Capital Expenditure, % | -6.57 | -8.59 | -7.7 | -7.73 | -9.5 | -8.02 | -8.02 | -8.02 | -8.02 | -8.02 |
| Tax Rate, % | 25.94 | 25.94 | 25.94 | 25.94 | 25.94 | 25.94 | 25.94 | 25.94 | 25.94 | 25.94 |
| EBITAT | 8,441.2 | 5,946.2 | 7,423.7 | 7,285.1 | 3,993.6 | 6,370.4 | 6,257.0 | 6,145.7 | 6,036.3 | 5,928.9 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -827.1 | 4,485.8 | 8,276.4 | 5,970.0 | 10,605.6 | 999.0 | 6,084.4 | 5,976.1 | 5,869.8 | 5,765.3 |
| WACC, % | 5.28 | 5.27 | 5.31 | 5.28 | 5.24 | 5.28 | 5.28 | 5.28 | 5.28 | 5.28 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 20,798.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 5,881 | |||||||||
| Terminal Value | 179,560 | |||||||||
| Present Terminal Value | 138,862 | |||||||||
| Enterprise Value | 159,660 | |||||||||
| Net Debt | 17,412 | |||||||||
| Equity Value | 142,248 | |||||||||
| Diluted Shares Outstanding, MM | 4,141 | |||||||||
| Equity Value Per Share | 34.35 |
What You Will Get
- Real GSK Financial Data: Pre-filled with GSK’s historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See GSK’s intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Comprehensive GSK Financials: Gain access to precise pre-loaded historical data and forward-looking projections.
- Adjustable Forecast Parameters: Modify highlighted cells for metrics such as WACC, growth rates, and profit margins.
- Real-Time Calculations: Automatic updates for DCF, Net Present Value (NPV), and cash flow analysis.
- Interactive Dashboard: User-friendly charts and summaries to help visualize your valuation insights.
- Designed for All Users: An intuitive layout tailored for investors, CFOs, and consultants alike.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered GSK data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for GSK’s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose GSK plc (GSK)?
- Innovative Research: GSK is at the forefront of scientific advancements in healthcare.
- Commitment to Quality: High standards in manufacturing ensure the safety and efficacy of products.
- Global Reach: GSK operates in numerous countries, providing access to vital medications worldwide.
- Patient-Centric Approach: Focused on improving patient outcomes through tailored healthcare solutions.
- Expertise in Biopharmaceuticals: Renowned for cutting-edge treatments and therapies in various therapeutic areas.
Who Should Use This Product?
- Professional Investors: Develop comprehensive and trustworthy valuation models for portfolio assessment related to GSK plc (GSK).
- Corporate Finance Teams: Evaluate valuation scenarios to inform internal strategic decisions for GSK plc (GSK).
- Consultants and Advisors: Deliver precise valuation insights for clients interested in GSK plc (GSK).
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling with GSK plc (GSK).
- Healthcare Enthusiasts: Gain insights into how pharmaceutical companies like GSK plc (GSK) are valued within the market.
What the Template Contains
- Comprehensive DCF Model: Editable template featuring detailed valuation calculations.
- Real-World Data: GSK plc’s (GSK) historical and projected financials preloaded for analysis.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics.
- Dashboard with Visual Outputs: Charts and tables providing clear, actionable results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.